Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial
Source: View publication →
In asymptomatic patients with left ventricular dysfunction following a myocardial infarction, long-term administration of the ACE inhibitor captopril significantly reduced all-cause mortality, recurrent infarction, and the development of severe heart failure.
Key Findings
Study Design
Study Limitations
Clinical Significance
The SAVE trial was a pivotal landmark that established ACE inhibitors as a cornerstone of secondary prevention for post-MI patients with left ventricular systolic dysfunction. It demonstrated that initiating captopril early and maintaining it long-term mitigates adverse cardiac remodeling, delays the onset of symptomatic heart failure, and significantly extends survival even in patients who are initially asymptomatic.
Historical Context
Prior to the SAVE trial, ACE inhibitors were predominantly reserved for patients suffering from severe, symptomatic heart failure or resistant hypertension. Supported by preclinical models showing that early ACE inhibition could prevent pathological ventricular enlargement (remodeling) after coronary occlusion, SAVE tested this hypothesis in humans. Published in 1992 during an era that also produced the SOLVD and CONSENSUS trials, SAVE helped shift the cardiology paradigm toward early, proactive neurohormonal blockade to alter the disease trajectory in high-risk cardiovascular patients.
Guided Discussion
High-yield insights from every perspective
By what physiological mechanism does captopril prevent the progression to overt heart failure in patients with asymptomatic left ventricular dysfunction post-myocardial infarction?
Key Response
Post-MI, the loss of functional myocardium triggers compensatory neurohormonal activation, notably the Renin-Angiotensin-Aldosterone System. Angiotensin II drives maladaptive ventricular remodeling, including hypertrophy, dilation, and fibrosis. By inhibiting ACE, captopril decreases Angiotensin II levels, thereby reducing afterload and directly mitigating this adverse structural remodeling, which preserves left ventricular geometry and function.
Based on the SAVE trial, if you are managing an asymptomatic patient 4 days post-MI with an ejection fraction of 35%, how should you adjust their medications and what specific laboratory monitoring is necessary?
Key Response
The SAVE trial proved that asymptomatic post-MI patients with an EF of 40% or less benefit from ACE inhibition to prevent future heart failure and death. The resident must initiate an ACE inhibitor like captopril. Crucially, this requires close monitoring of basic metabolic panels to watch for acute kidney injury and hyperkalemia, as ACE inhibitors decrease efferent arteriolar tone and reduce aldosterone secretion, posing risks to borderline hemodynamically stable post-MI patients.
The SAVE trial demonstrated an unexpected secondary outcome of reduced recurrent myocardial infarction rates. Given that ACE inhibitors are primarily vasodilators, what are the advanced mechanistic theories explaining this anti-ischemic benefit?
Key Response
While initially surprising, the reduction in recurrent MI is thought to be multifactorial. Mechanisms include improved endothelial function and vasodilation due to decreased bradykinin degradation, stabilization of atherosclerotic plaques by reducing Angiotensin II-mediated oxidative stress and inflammation, decreased sympathetic tone, and a reduction in myocardial oxygen demand secondary to diminished ventricular wall stress (Laplace's Law) from attenuated LV dilation.
While the SAVE trial established captopril's efficacy post-MI, modern practice utilizes agents like lisinopril or ramipril. How do you teach residents to critically evaluate when a drug-specific trial can be safely extrapolated as a class effect in cardiovascular medicine?
Key Response
This question prompts learners to differentiate between drug-specific and class effects. Attending physicians should teach that subsequent trials (such as AIRE for ramipril and TRACE for trandolapril) were needed to confirm that mortality benefit post-MI is indeed a neurohormonal class effect of ACE inhibitors. We now use newer agents primarily for their longer half-lives and once-daily dosing, which drastically improves patient adherence compared to the TID dosing of captopril used in SAVE.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The SAVE trial utilized a placebo-controlled design to evaluate captopril. How does the ethical impossibility of using a placebo control in modern post-MI HFrEF populations alter the statistical approach and sample size requirements for contemporary cardiovascular trials?
Key Response
Because SAVE and similar trials established RAAS blockade as the standard of care, modern trials cannot ethically withhold this therapy. Consequently, new interventions must be tested on top of guideline-directed medical therapy (active comparator). This requires massive sample sizes to detect increasingly marginal incremental benefits (superiority) or relies on complex non-inferiority designs with carefully justified margins, making modern trial execution statistically and logistically much more challenging.
As a peer reviewer evaluating the SAVE trial today, how would you critique the deliberate exclusion of patients with baseline severe renal dysfunction or overt heart failure regarding the study's external validity?
Key Response
A stringent reviewer would highlight that while the exclusion criteria maximized internal validity and safety by avoiding patients at highest risk for captopril-induced AKI or hyperkalemia, it severely limits external validity. The results cannot be universally applied to the sickest post-MI patients with cardiorenal syndrome, requiring editors to ensure the authors strictly confine their clinical claims to stable, asymptomatic individuals with mild-to-moderate LV dysfunction.
How did the findings of the SAVE trial directly shape current ACC/AHA guidelines for the management of patients following an acute myocardial infarction, and what is the specific Class and Level of Evidence for this intervention?
Key Response
The SAVE trial is a foundational pillar that led to the ACC/AHA guideline assigning a Class I, Level of Evidence A recommendation for the initiation of ACE inhibitors in all post-MI patients with a reduced ejection fraction (less than or equal to 40%). By demonstrating that early intervention in asymptomatic patients prevents fatal and non-fatal heart failure events, SAVE fundamentally shifted guidelines toward proactive neurohormonal blockade rather than purely symptom-reactive management.
Clinical Landscape
Noteworthy Related Trials
AIRE Trial
Tested
Ramipril
Population
Patients with clinical evidence of heart failure after acute myocardial infarction
Comparator
Placebo
Endpoint
All-cause mortality
TRACE Trial
Tested
Trandolapril
Population
Patients with left ventricular dysfunction following acute myocardial infarction
Comparator
Placebo
Endpoint
All-cause mortality
VALIANT Trial
Tested
Valsartan, captopril, or the combination of both
Population
Patients with heart failure or left ventricular dysfunction after myocardial infarction
Comparator
Captopril
Endpoint
All-cause mortality
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis